Formulary
Avatrombopag: Indications, Dosing, Side Effects and Interactions
Avatrombopag is a thrombopoietin receptor agonist that binds to and activates the thrombopoietin (TPO) receptor, thereby increasing platelet production.
MedNext Academy | 3 min read
Avatrombopag: Indications, Dosing, Side Effects and Interactions
Avatrombopag is a thrombopoietin receptor agonist that binds to and activates the thrombopoietin (TPO) receptor, thereby increasing platelet production.
Drug action
Avatrombopag is a thrombopoietin receptor agonist that binds to and activates the thrombopoietin (TPO) receptor, thereby increasing platelet production.
Indications and dose
**Thrombocytopenia [in patients with chronic liver disease undergoing invasive procedures and platelet count less than 40x109/litre] (under expert supervision)**
- **Adult** (By Mouth): Thrombocytopenia [in patients with chronic liver disease undergoing invasive procedures and platelet count less than 40x10 9 /litre] (under expert supervision) 60 mg once daily for 5 days, treatment to be started 10 to 13 days before procedure; procedures to be carried out 5 to 8 days after the last dose of avatrombopag.
**Thrombocytopenia [in patients with chronic liver disease undergoing invasive procedures and platelet count between 40 to 50x109/litre] (under expert supervision)**
- **Adult** (By Mouth): Thrombocytopenia [in patients with chronic liver disease undergoing invasive procedures and platelet count between 40 to 50x10 9 /litre] (under expert supervision) 40 mg once daily for 5 days, treatment to be started 10 to 13 days before procedure; procedures to be carried out 5 to 8 days after the last dose of avatrombopag.
**Chronic immune (idiopathic) thrombocytopenic purpura in patients refractory to other treatments (such as corticosteroids or immunoglobulins) (under expert supervision)**
- **Adult** (By Mouth): 20 mg once daily, dose to be adjusted to achieve a platelet count of 50x10 9 /litre or more-consult product literature for dose adjustments, discontinue if inadequate response after 4 weeks treatment at maximum dose, or if platelet count more than 250x10 9 /litre after 2 weeks of dosing at 20 mg once weekly; maximum 40 mg per day.
Cautions
General cautions: Known genetic polymorphisms-consult product literature; risk factors for thromboembolism Specific cautions: When used for Thrombocytopenia in patients with chronic liver disease undergoing invasive procedures Administration before laparotomy, thoracotomy, open-heart surgery, craniotomy, or excision of organs (no clinical experience)
Side effects
Common or very common Fatigue Uncommon Anaemia; bone pain; fever; myalgia; portal vein thrombosis
Pregnancy
Avoid-limited information available. M
Breast feeding
Avoid-present in milk in animal studies. M
Hepatic impairment
Caution in severe impairment (limited information available). M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Avatrombopag in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

